Letter | Published:

Molecular mechanism of physiological fibrinolysis

Nature volume 272, pages 549550 (06 April 1978) | Download Citation

Subjects

Abstract

THE proteolytic enzyme system in blood that is predominantly responsible for removal of fibrin deposits, is called the fibrinolytic system. This system consists of three main components: the proenzyme plasminogen, which can be activated by limited proteolysis to the proteolytic enzyme plasmin; plasminogen activators, the most important of which probably originates in the endothelial cells; and inhibitors, which can rapidly neutralise plasmin or interfere with the activation of plasminogen. The proteolytic enzyme plasmin has a broad specificity, which is not very different from that of trypsin. However, in vivo the main target of plasmin is fibrin. Three hypotheses have been put forward to explain this specificity. Alkjaersig et al.1 have suggested that plasminogen is adsorbed to polymerising fibrin and converted to active enzyme by activators which diffuse into the thrombus. Plasmin would then exert its action in an environment relatively free of inhibitors. Ambrus and Markus2 have proposed that plasmin–inhibitor complexes formed in the circulation dissociate in the presence of fibrin, because plasmin has a greater affinity for fibrin than for its inhibitors. Chesterman et al.3 suggested that the activators bind selectively to fibrin and transform plasminogen, which diffuses into the thrombus, to plasmin. During the past few years specific interactions at the molecular level have been demonstrated between the different components of the fibrinolytic system. These findings now enable us to formulate a molecular model for the regulation of fibrinolysis in vivo.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , & J. clin. Invest. 38, 1086–1095 (1959).

  2. 2.

    & Am. J. Physiol. 199, 491–494 (1960).

  3. 3.

    , & Nature new Biol. 238, 15–17 (1972).

  4. 4.

    Biochim. biophys. Acta 393, 55–65 (1975).

  5. 5.

    & Thromb. Res. 10, 213–222 (1977).

  6. 6.

    , & Biochim. biophys. Acta 540, 295–300 (1978).

  7. 7.

    Thromb. Diath. Haemorrh. 33, 573–585 (1975).

  8. 8.

    , , , & in Progress in Chemical Fibrinolysis and Thrombolysis (eds Davidson, J. F., Rowan, R. M., Samama, M. M. & Desnoyers, P. C.) (Raven, New York, in the press).

  9. 9.

    & Eur. J. Biochem. 50, 489–494 (1975).

  10. 10.

    , & Thromb. Diath. Haemorrh. 28, 65–74 (1972).

  11. 11.

    in Thrombosis and Urokinase (eds Paoletti, R. & Sherry, S.) 91–102 (Academic, London, 1977).

  12. 12.

    & Presented at the 3rd Woudschoten Conference on Screening Methods for Detection of a Tendency to Thrombosis, Utrecht The Netherlands, 26–29 October (1977).

  13. 13.

    Eur. J. Biochem. 69, 209–216 (1976).

  14. 14.

    & J. biol. Chem. 251, 5956–5965 (1976).

  15. 15.

    & Biochem. J. 159, 545–553 (1976).

  16. 16.

    & Eur. J. Biochem. 78, 19–26 (1977).

  17. 17.

    & Thromb Res. 10, 851–856 (1977).

  18. 18.

    & Biochem. J. 163, 389–391 (1977).

  19. 19.

    & Eur. J. Biochem 84, 573–578 (1978).

Download references

Author information

Affiliations

  1. Department of Medical Chemistry, Umeå University, Sweden, and Center for Thrombosis and Vascular Research, University of Leuven, Belgium

    • BJÖRN WIMAN
    •  & DÉSIRÉ COLLEN

Authors

  1. Search for BJÖRN WIMAN in:

  2. Search for DÉSIRÉ COLLEN in:

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/272549a0

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.